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Background: Exportin 1 (XPO1, also known as CRM1), is a chaperone protein responsible for the export of over 200
target proteins out of the nucleus. The expression and activity of XPO1 is upregulated in several human cancers
and its expression is also linked to the development of chemotherapy resistance. Recent studies using both human
and murine cancer cell lines have demonstrated that XPO1 is a relevant target for therapeutic intervention. The
present study sought to characterize the biologic activity of an orally bioavailable selective inhibitor of nuclear
export (SINE), KPT-335, against canine melanoma cell lines as a prelude to future clinical trials in dogs with melanoma.
Results: We evaluated the effects of KPT-335 on 4 canine malignant melanoma cell lines and found that KPT-335
inhibited proliferation, blocked colony formation, and induced apoptosis of treated cells at biologically relevant
concentrations of drug. Additionally, KPT-335 downregulated XPO1 protein while inducing a concomitant increase in
XPO1 messenger RNA. Lastly, KPT-335 treatment of cell lines upregulated the expression of both protein and mRNA for
the tumor suppressor proteins p53 and p21, and promoted their nuclear localization.
Conclusions: KPT-335 demonstrates biologic activity against canine melanoma cell lines at physiologically relevant
doses, suggesting that KPT-335 may represent a viable treatment option for dogs with malignant melanoma.
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Canine oral malignant melanoma is a biologically aggres-
sive tumor with a reported metastatic rate of up to 90%
[1]. Local disease can be treated with surgery and coarse-
fractionated radiation therapy, with success dependent on
location and stage [1]. Despite options for local control
most dogs will eventually die of metastatic disease [2].
Similar to the case with human malignant melanoma, the
use of traditional chemotherapy agents, such carboplatin
and cisplatin, has little impact on both the primary tumor
and metastatic disease, with no substantial survival benefit
[3-7]. Other treatment strategies, such as immunotherapy
using a variety of vaccine based approaches, including
the commercially available xenogeneic melanoma vaccine* Correspondence: london.20@osu.edu
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unless otherwise stated.(Oncept), have been explored as options for the manage-
ment of canine malignant melanoma [8-10]. While the
Oncept vaccine was proven to be safe and preliminary
data indicated that it significantly enhanced survival when
used in the setting of loco-regional control, [11] a recent
retrospective clinical study failed to replicate these find-
ings dogs with oral melanoma that had loco-regional
tumor control [10-14]. There is also limited data in which
small molecule inhibitors such as toceranib phosphate
(Palladia) have been used to treat this disease in dogs, al-
though formal data regarding efficacy is lacking [15,16].
Therefore, new therapeutic approaches to treatment are
needed.
Recently, the protein exportin 1 (XPO1, also called
Chromosome Region Maintenance protein 1 [CRM1]) has
been validated as a target for therapeutic intervention in
cancer. XPO1 is one of seven known nuclear export pro-
teins responsible for shuttling cargo from the nucleus tod. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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β family of transport receptors that binds over 200 target
proteins through a hydrophobic leucine-rich nuclear export
signal (NES) present in the cargo [20]. XPO1 is the sole nu-
clear exporter of several major tumor suppressor and
growth regulatory proteins (TSPs and GRPs), including
p53, p75, Rb, p21, p27, STAT3, FOXO and IκB among
others [21,22]. There is now substantial data demonstrating
that XPO1 is upregulated in both hematologic malignancies
and solid tumors [17-19]. Furthermore, overexpression of
XPO1 correlates with a poor prognosis in many human
cancers, indicating that changes in nuclear-cytoplasmic
trafficking resulting in aberrant localization of key proteins
can contribute to cancer development and progression.
Given the role of XPO1 dysregulation in cancer, there has
been great interest in developing inhibitors of this protein.
Recently, novel orally bioavailable, small-molecule selective
inhibitor of nuclear export (SINE) compounds that specific-
ally bind to XPO1 at the reactive site Cys 528 residue have
been developed and tested both in vitro and in vivo [23-29].
SINE compounds induce apoptosis and block proliferation
in several cancer cell lines, including those derived from
colon [21], pancreas [23], and breast carcinomas [27] as well
as chronic lymphocytic leukemia (CLL) [26], while sparing
normal cells [30]. Additional studies have shown potent
anti-cancer activity and good tolerability of SINE in vivo
using mouse human xenograft (subcutaneous, orthotopic,
or leukemograft) models of pancreatic cancer [23], renal
cancer [31], CLL [26], mantle cell lymphoma (MCL) [29],
multiple myeloma [32] and acute myelogenous leukemia
(AML) [28]. Early clinical trials of the SINE KPT-330 (seli-
nexor) have demonstrated biologic activity of XPO1 inhib-
ition in human lymphoid malignancies.
The SINE compound KPT-335 (verdinexor, closely
related to selinexor) has been previously evaluated in ca-
nine lymphoma cell lines and found to have good activ-
ity in the low nanomolar range [33]. Additionally, a
phase I clinical trial of KPT-335 in dogs with primarily
lymphoma demonstrated evidence of single agent activity
consisting of both partial response to therapy and stable
disease for over 4 weeks with excellent tolerability over
long-term dosing. Lastly, data generated in both healthy
dogs and dogs with cancer indicate that KPT-335 exhibits
good oral bioavailability with an average Cmax of approxi-
mately 250 ng/ml and an average AUC of 1800 ng/ml
[33]. The purpose of this study was to evaluate the activity
of KPT-335 against established canine malignant melan-
oma cell lines as a prelude to future testing in dogs with
metastatic melanoma.
Methods
Cell lines and reagents
Canine melanoma cell lines Mel 23, Mel 36, Mel 69 and
Mel 83 were generously provided by Michael S. Kent(UC Davis School of Veterinary Medicine, Davis, CA)
[34-36]. Three of the lines (Mel 23, 69 and 83) were de-
rived from a primary oral tumor and Mel 36 was gener-
ated from a metastatic lymph node. The cell lines were
maintained in RPMI 1640 supplemented with 10% FBS,
non-essential amino acids, sodium pyruvate, penicillin,
streptomycin, L-glutamine, and Hepes (4-(2-hydroxythyl)-
1-piperazineethanesolfonic acid) at 35°C, supplemented with
5% CO₂. KPT-335 (provided by Karyopharm Therapeutics,
Inc, Natick, MA) was dissolved in DMSO to generate
stock solutions for use in vitro. The following antibodies
were used for Western blotting and immunofluores-
cence experiments: anti-p53, anti-p21, anti-XPO1, and
anti- β-actin (all from Santa Cruz Biotechnology, Santa
Cruz, CA).
Cell proliferation assay
Melanoma cells (1.5 × 103) were seeded in triplicate in 96-
well plates overnight in 10% FBS supplemented media and
incubated with DMSO or increasing concentrations of
KPT-335. After 72 or 96 hours, the medium was removed
and the plates were frozen at −80°C overnight before
processing using the CyQuant® Cell Proliferation
Assay Kit (Molecular Probes, Eugene, OR) according
to the manufacturer’s instructions. Cell proliferation was
calculated as a percentage of the DMSO-treated control
wells and IC₅₀ values were derived after plotting prolifera-
tion values on a logarithmic curve. Each experiment was
repeated 3 times.
Assessment of apoptosis
The ability of KPT-335 to induce apoptosis in treated
cells was assessed using annexin V/propidium iodide
(PI) staining as previously described [37]. Briefly, 1.0 ×
106 canine melanoma cells were treated with 0.1%
DMSO, 0.1 μM KPT-335, or 1 μM KPT-335 for 96 hours
at 37°C. Cells were collected, washed, and stained with
annexin V–fluorescein isothiocyanate and PI for 15 mi-
nutes before evaluation by flow cytometry on a Becton
Dickinson FACS Caliber. Each experiment was repeated
3 times.
Immunoblotting
Melanoma cells (2 × 106) in 10% FBS medium were
treated with DMSO, 0.1 μM or 1 μM KPT-335 for 4 or
24 hours. Protein lysates were prepared and quantified,
separated by SDS-PAGE, and Western blotting was per-
formed using previously described methods [38]. The
membranes were incubated overnight with anti-XPO1,
anti-p53 or anti-p21 antibodies, then incubated with the
appropriate horseradish peroxidase linked secondary anti-
bodies, washed, and exposed to substrate (SuperSignal
West Dura Extended Duration Substrate, Pierce, Rockford,
IL). Blots were stripped, washed, and reprobed for β-actin.
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Total RNA was extracted from canine melanoma cells
that were cultured in 10% FBS supplemented medium
for 4 or 24 hours with DMSO, 0.1 μM or 1 μM KPT-
335, using TRIzol (Invitrogen). cDNA was made from
2 μg of total RNA using Superscript III (Invitrogen),
followed by real-time PCR with TaqMan-specific probes
(Applied Biosystems) according to the manufacturer’s
protocol. Real-time PCR for XPO1 was performed using
the Applied Biosystems StepOne Plus Detection System
and MIC-1 and p21 expression was detected using the
ViiA™ 7 Real-Time PCR System (Life Technologies).
Normalization was performed relative to 18S rRNA. All
reactions were performed in triplicate and included no-
template controls for each gene. Relative gene expression
for all real-time PCR data was calculated using the com-
parative threshold cycle method [39].
Immunofluorescence
Cells were plated in a 24 well plate with poly-lysine coated
coverslips (35,000-50,000 cells per well) then treated with
DMSO or 1 μM KPT-335. They were then fixed with 4%
paraformaldehyde and permeabilized with 0.2% Triton-X.
Next, the cells were blocked at room temperature in block-
ing buffer (1x PBS/5% bovine albumin/0.3% Triton-x) for
30 minutes and then were incubated with anti-p53 or anti-
p21 for 1 hour at room temperature. A secondary
FITC labeled anti-rabbit or anti-goat antibody was ap-
plied for 30 minutes, as appropriate (Alexa Fluor® 488
goat anti-rabbit IgG Invitrogen or Alexa Fluor® 488
donkey anti-goat IgG Invitrogen). Cells were also stained
with DAPI to visualize the nucleus (ProLong® Gold antifade
reagent with DAPI Invitrogen). Intracellular localization
of proteins was analyzed by immunofluorescence mi-
croscopy using an Olympus FV1000 Spectral confocal
microscope.
Clonogenic assay
Melanoma cell lines were grown in flasks until 80% con-
fluent, then collected, washed and plated at 2,000 cells
per well in six-well plates. After 24 hours the cells were
treated with DMSO, 1 nM, 10nM, 0.1 μM, 1 μM or
10 μM KPT 335 and incubated at 35°C, supplemented
with 5% CO₂ for 7 days. Cells were then fixed with
methanol/acetic acid (3:1), washed with PBS and stained
with crystal violet (0.5%). The surviving cell fraction was
defined as the number of colonies counted divided by
the number of cells that were plated in the treated
groups and then normalized to the plating efficiency.
Plating efficiency was defined as the number of colonies
divided by the number of cells plated in the untreated
group [34,35]. Vehicle control treated Mel 23 and 36
cells served as the plating efficiency control group. Ex-
periments were performed in triplicate.Statistics
All experiments were performed 3 times and/or performed
in triplicate. A mean and standard deviation was derived
from all repeated experiments. The apoptosis assays and
clonogenic assays were evaluated using a Student’s t-test to
compare treated groups to vehicle control. A one-way
ANOVA comparison test was used to evaluate differences
in gene expression among the KPT-335 treated and vehicle
control treated groups for the quantitative RT-PCR assays
and to compare multiple treatment groups in the cell pro-
liferation assays. Values of p < 0.05 were considered statisti-
cally significant.
Ethical support
All the studies we performed were in vitro with cell lines
and as such, no IACUC or approval was necessary. The
cell lines have been available for several years and have
been used in prior publications.
Results
KPT-335 inhibits the proliferation of canine melanoma
cell lines
To assess whether KPT-335 was capable of inhibiting
the proliferation of canine melanoma cells, the tumor
cell lines were treated with increasing concentrations of
KPT-335 and the CyQUANT assay was used to assess
relative cell numbers after 96 hours of culture. As demon-
strated in Figure 1, proliferation of all cell lines was signifi-
cantly inhibited at concentrations in the nanomolar range.
The IC₅₀ values for the various cell lines ranged from
0.071-0.330 μM.
XPO1 inhibition induces apoptosis of canine melanoma
cell lines
To determine if inhibition of XPO1 resulted in apoptosis
of canine melanoma cell lines, cells were treated with
DMSO, 0.1 μM KPT-335 or 1 μM KPT-335 for 96 hours.
Following collection, they were stained with markers of
early (AnnexinV) and late (propidium iodide) apoptosis
and then analyzed by flow cytometry. Figure 2 demon-
strates that treated cells exhibited significant increases in
early and late apoptosis when compare to the vehicle
control in the 0.1 μM and 1 μM treatment group, with
the exception of Mel 69 which only had a significant in-
crease in late apoptosis in the 1 μM treatment group.
Colony formation is inhibited by KPT-335
Mel 36 and Mel 23 previously have been demonstrated
to exhibit colony formation in culture and inhibition of
colony growth has been used as a tool to assess the ef-
fects of various treatments including rapamycin, nutilin-
3 and DNA damaging agents on these canine melanoma
cell lines [34,35]. To determine whether blocking XPO1
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Figure 1 KPT-335 inhibits proliferation of canine melanoma cells. Canine melanoma cell lines were treated with DMSO or KPT-335 at increasing
concentrations for 96 hours then analyzed using the CyQUANT® cell proliferation kit. Proliferation values are listed as a percentage of DMSO control.
Experiments were performed in triplicate and repeated three times. For each cell line there was a significant decreasing trend in cell proliferation with
dose of KPT-335 (p < 0.0001).
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with DMSO or KPT-335 and evaluated daily. After 7 days
of culture the plates were collected and colonies were
counted following staining with crystal violet. A signifi-
cant inhibition of colony formation occurred in cells ex-



























Figure 2 KPT-335 induces apoptosis of canine melanoma cells. Canine
1 μM KPT-335 for 96 hours. Cells were collected and stained with Annexin
early and late apoptosis. Cells treated with KPT-335 at 0.1 μM and 1 μM de
to vehicle treated cells (p < 0.05; with the exception of the Mel 69 in whichKPT-335 downregulates XPO1 protein expression while
inducing a concomitant increase in XPO1 mRNA
Previous work has shown that XPO1 inhibition by SINE
compounds results in loss of target protein, while simul-
taneously inducing upregulation of XPO1 gene expression
[32]. Furthermore, increased expression of XPO1 mRNA
has been used as a pharmacodynamic marker in people0 0.1 1 0 0.1 1




melanoma cell lines were treated with DMSO, 0.1 μM KPT-335 or
V FITC/propidium iodide and analyzed by flow cytometry to quantitate
monstrated a substantial increase in early and late apoptosis compared
only the 1 μM late apoptosis group showed statistical significance).
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Figure 3 Effect of KPT-335 on colony formation. Canine Mel 23
and Mel 36 cells were seeded at 2,000 cells per well in a 6 -well
plate for 24 hours, followed by treatment with DMSO, 0.001, 0.01,
0.1, 1 or 10 μM KPT-335 for 7 days. Cells were then fixed and stained
with crystal violet and colonies with greater than 50 cells were
counted. The surviving cell fraction was defined as the number of
colonies counted divided by the number of cells that were plated in
the treated groups and then normalized to the plating efficiency.
Plating efficiency was defined as the number of colonies divided by
the number of cells plated in the untreated group. Vehicle control
treated Mel 23 and Mel 36 cells served as the plating efficiency
control group. The surviving fraction was significantly decreased in
cells treated with > 10 nM concentration of KPT-335, p < 0.05.
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(selinexor) [40]. To determine whether KPT-335 has a
similar effect on XPO1 in canine melanoma cell lines,
cells were incubated with DMSO or KPT-335 at 0.1 μM
or 1 μM for 4 and 24 hours. Figure 4A demonstrates a
time and dose dependent loss of protein expression in
treated cells. Concordant with results in human cell lines,
XPO1 mRNA was similarly upregulated in the melan-
oma cells following incubation with KPT-335 for 24 hours
(Figure 4B), demonstrating a compensatory response to
loss of XPO1 protein.
KPT-335 modulates the expression of p53 and its
downstream targets and localization of p53 and p21 in
canine melanoma cell lines
Consistent with previous work, only 3 of the 4 lines
expressed p53 protein [34]. KPT-335 treatment en-
hanced p53 expression in two of these lines after
24 hours of culture (Figure 5A). Quantitative RT-PCR
showed that expression of the targets p21 and MIC-1
was significantly upregulated after canine melanoma cell
lines were treated with DMSO or KPT-335 at 0.1 μM or
1 μM for 4 hours (Mel 69) or 24 hours (Mel 23 and Mel
83) (Figure 5B). Mel 69 was collected at an earlier time
point because this cell line grew at a much faster rate
than the other lines so overgrowth in the vehicle control
group was a problem at later time points of collection.
MIC-1 was only significantly increased in Mel 23 and
Mel 69. Similarly, p21 was expressed in 3 of the 4 lines
and exposure to KPT-335 increased its expression. Evalu-
ation of nuclear versus cytoplasmic protein in treated cells
revealed that with drug treatment both p53 and p21
expression were increased primarily in the nucleus, al-
though levels were somewhat enhanced in the cytoplasm
as well (Figure 5C). Lastly, confocal microscopy confirmed
that p53 and p21 did demonstrate enhanced nuclear
localization after KPT-335 treatment in Mel 23 and
Mel 69 (Figure 6).
Discussion
Unlike malignant melanoma in humans which occurs
primarily in the skin and is typically associated with ex-
posure to UV irradiation, malignant melanoma in dogs
occurs primarily in the oral cavity and nail beds [1]. Ap-
proximately 60% of human cutaneous melanomas pos-
sess activating mutations in the cytoplasmic kinase
BRAF whereas these mutations are not found in the ca-
nine disease [41,42]. In both dogs and people, standard
chemotherapy agents do not have substantial activity in
either the primary disease or in the setting of metastasis
[1,3-7,43]. While there are significant differences that
exist between the clinical presentation and molecular
biology of human and canine malignant melanoma, two
recent review articles demonstrated that the diseases
KPT-335 (µM)
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0 0.1 1 0 0.1 1











































Figure 4 Impact of KPT-335 on XPO1 message and protein expression in melanoma cell lines. A. Canine melanoma cell lines were treated
with DMSO or KPT-335 1 μM for 24 hours and RNA was collected. Quantitative RT-PCR was performed for XPO1. Relative expression was found to
be increased in treated cell lines with a p< 0.05. B. Canine melanoma cell lines were treated with DMSO or KPT-335 at 0.1 μM or 1 μM for 4 or
24 hours prior to collection. Protein lysates were generated, separated by SDS-PAGE and Western blotting for XPO1 and β-actin were performed.
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ations in both AKT and MAPK signaling pathways, with
RAS and PTEN mutations present in tumors from both
species [42,44].
In human patients with melanomas that carry BRAF
mutation the small molecule BRAF inhibitor vemurafe-
nib (Zorafenib) has shown significant activity with re-
sponse rates of approximately 50%. Unfortunately, these
responses tend to be short-lived, and most patients relapse
within 8–12 months [45,46]. More recently, monoclonal
antibodies that block signaling of CTLA4 (ipilumimab,
Yervoy) and PD1 (nivolumab) have induced durable clin-
ical remissions in human patients with widely disseminated
metastatic melanoma; when the two antibodies were
combined, response rates were over 40% and in many
instances, were durable [47,48].
There are currently no monoclonal antibodies that block
CTLA4 or PD1 available for use in veterinary medicine,and while the chemotherapy agent carboplatin has dem-
onstrated some activity against primary oral malignant
melanoma in dogs, there is no definitive evidence that any
chemotherapy agents work in the microscopic disease set-
ting. Recently, the Oncept xenogeneic melanoma vaccine
was approved for use in dogs with oral malignant melan-
oma in the adjuvant setting following control of the pri-
mary tumor/local disease [49]. However, many dogs still
develop widespread metastatic disease necessitating the
development of new therapeutic approaches.
Selective inhibitor of nuclear export (SINE) compounds
that target the nuclear export protein XPO1 represent a
potential target for therapeutic intervention in canine and
human melanoma. Several studies have demonstrated that
treatment of tumor cell lines with SINE compounds results
in enhanced expression of p21 and p53, and redistribution
of these proteins into the nucleus [26,28,29,31,32,45]. With
respect to melanoma, both p53 and retinoblastoma protein
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Figure 5 Evaluation of p53 and p21 expression and localization in canine melanoma cell lines after KPT-335 treatment. A. Canine
melanoma cell lines were treated with DMSO or 1 μM KPT-335 for 24 hours prior to collection. Protein lysates were generated, separated by
SDS-PAGE and Western blotting for p53, p21 and β-actin were performed. B. Canine melanoma cell lines were treated with DMSO or KPT-335 at
0.1 μM or 1 μM for 4 hours (Mel 69) or 24 hours (Mel 23 and Mel 83). RNA was collected and quantitative RT-PCR was performed for MIC-1 and
relative expression of MIC-1 was significantly increased in Mel 23 and Mel 69 cells treated with 0.1 μM and 1 μM KPT-335 and MIC-1 was signifi-
cantly increase in Mel 23 and Mel 69 cells treated with 0.1 μM and 1 μM (p < 0.05). C. Canine melanoma cell lines were treated with DMSO or
1 μM KPT-335 for 24 hours prior to collection. Nuclear and cytoplasmic protein lysates were generated and separated by SDS-PAGE and Western
blotting for p53, p21 and β-actin was performed.
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http://www.biomedcentral.com/1746-6148/10/160(Rb) undergo increased nuclear export preventing them
from engaging in active tumor suppression [50]. In canine
melanoma p53 was shown to be excluded from the nucleus
in 7 cell lines and 18 of 25 tumor samples [51]. The im-
portance of p53 activity independent of mutation status
has been demonstrated in human melanoma and therapiesthat increase the activity of this protein have shown prom-
ise [52-54]. Following treatment of human melanoma lines
with a variety of SINE compounds (KPT-185, −251, −276,
330) in combination with a small molecule BRAF inhibitor,
stabilization of p53 was shown to be at least partly respon-



























































Figure 6 Confocal microscopy to detect p21 and p53 cellular localization following KPT-335 treatment of melanoma cell lines. The
canine melanoma cell lines Mel 23 and Mel 69 were treated with DMSO or 1 μM KPT-335 for 24 hours. Cells were fixed and stained with ant-p21
(A) or anti-p53 (B) and then a secondary FITC conjugated antibody. Cells were then counterstained with DAPI to identify the nucleus. Images
were obtained using an Olympus FV1000 Spectral confocal microscope and overlayed to assess protein localization.
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ition was found to be synergistic, also altering the expres-
sion of Rb and survivin [45].Given the similarity of canine and human melanoma
with respect to tumor suppressor dysregulation, we were
interested in determining whether SINE compounds
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cells. Several SINE compounds have been tested in vitro
and found to have good activity at nanomolar concentra-
tions against human prostate, renal, pancreatic, and breast
cancer cell lines, as well as against a variety of cell lines
representing hematopoietic malignancies (CLL, mantle
cell lymphoma, NHL, AML) [25-28,30,31]. Currently, the
SINE compound KPT-330 (selinexor) is undergoing evalu-
ation in human clinical trials, while the SINE compound
KPT-335 (verdinexor) has completed both phase 1 and 2
canine clinical trials. Significant activity against canine
NHL was observed in vitro in the low nanomolar range
against canine diffuse large B cell lymphoma (DLBCL)
samples, as well as in a canine DLBCL cell line [33]. In the
phase 1 setting, partial response to KPT-335 was observed
in dogs with NHL, and unlike previously tested XPO1
inhibitors such as leptomycin B [55], KPT-335 exhibited
good tolerability with anorexia and weight loss as the
main clinical effects noted [33]. Based on these findings,
we elected to evaluate the potential utility of this SINE
compound in canine melanoma lines prior to clinical test-
ing in dogs with melanoma.
In the current study we found that KPT-335 inhibited
the proliferation of canine melanoma cell lines with IC50
concentrations ranging from 71–330 nM. These doses
are biologically relevant and achievable based on phar-
macokinetic data derived from studies in both healthy
dogs and dogs enrolled in the phase 1 and 2 studies [33].
Furthermore, we demonstrated that KPT-335 induced
apoptosis of the melanoma cell lines, although these ef-
fects were somewhat delayed, occurring at 72–96 hours
after drug exposure. This delay in effect is concordant
with prior data generated in human melanoma lines in
which BCL-2 was not down regulated until 32 hours fol-
lowing exposure to SINE compounds [56]. Additionally,
in human leukemia cell lines treated with SINE com-
pounds, cycle arrest was noted at 24 hours but IC₅₀ values
were best at 48 and 72 hours [45].
Although significant changes in proliferation or apop-
tosis were not found until 72–96 hours after drug expos-
ure, the melanoma cell lines demonstrated changes in
gene and protein expression at much earlier time points.
This is likely a consequence of the manner in which
tumor cells are disrupted. Inhibition of XPO1 results in
a redistribution of nuclear proteins and consequently, an
impact on gene transcription, largely due to restoration
of tumor suppressor protein localization. This initiates a
genome survey to determine whether sufficient critical
non-repairable errors exist that necessitate induction of
apoptosis. During this time, the cells may be able to
compensate for changes in nuclear and cytoplasmic
localization of key proteins for a period of time through
such mechanisms as autophagy, until a critical point is
reached and the process of apoptosis is initiated [57].The mechanism of action of XPO1 inhibitors is thus
substantially different from that associated with small
molecules that block known “driver” proteins often con-
stitutively active through mutation, translocation or
overexpression. In these cases, blocking the function of
the driver protein typically results in rapid cell death as
the tumor cell has become reliant on that particular pro-
tein for survival.
As expected, treatment of melanoma lines with KPT-
335 increased the protein expression of p53 and p21 and
the mRNA of p21 and MIC-1. There also was enhanced
nuclear translocation of p21 and p53. Interestingly, the
Mel 36 line, previously reported to be p53 null [34], was
found to have basal p53 protein expression that in-
creased after drug exposure. The reason for this discrep-
ancy is not known, although it is possible there have
been alterations in gene expression profiles over time.
The effects of XPO1 inhibition on expression of these
tumor suppressor proteins have been well-documented
in a variety of human tumor cell lines treated with SINE
compounds and this is likely a significant contributor to
loss of cell viability [26,28,29,31,32,45]. Prior studies with
leptomycin B showed that prostate and neuroblastoma
human tumor cell lines exhibited upregulation and acti-
vation of p53 that directly contributed to growth arrest
and apoptosis [58,59]. In contrast, apoptosis after inhib-
ition of XPO1 can occur regardless of p53 status in some
tumor lines indicating that this is not the sole mechanism
for cell death [58]. Human melanoma cell lines were
shown to undergo apoptosis after SINE compound expos-
ure regardless of p53 status and other mechanisms such
as enhanced PUMA expression and decreased activation
of NF-ĸB were found to be responsible [32]. These data
are concordant with our studies as all melanoma lines
treated underwent apoptosis independent of p53 status.
In addition to effects on transcription factors, our data
demonstrate a direct effect of KPT-335 on its target pro-
tein, XPO1. Downregulation of XPO1 protein was ob-
served in melanoma cell lines as early as 4 hours after
drug exposure and expression was nearly completely
eliminated by 24 hours of treatment. These findings are
concordant with those generated in human myeloma
cells treated with the KPT-185 and KPT-330 [32]. Simi-
larly, human myeloma cells treated with the reversible
XPO1 inhibitor CBS9106 exhibited downregulation of
protein that was dependent on the ubiquitin/proteasome
pathway [60]. While protein was decreased, messenger
RNA for XPO1 was increased in the canine melan-
oma lines following KPT-335 exposure, a finding also
observed in human cell lines treated with the SINE com-
pounds [32]. This likely represents a compensatory mech-
anism associated with loss of functional XPO1 protein.
In fact, upregulation of XPO1 message is now being
used as a biomarker of target inhibition in ongoing
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(selinexor) [40].
Conclusion
In summary, KPT-335 (verdinexor), a novel orally bio-
available XPO1 inhibitor exhibits good in vitro single
agent activity against canine malignant melanoma cell
lines as evidenced by inhibition of proliferation and in-
duction of apoptosis. KPT-335 downregulated XPO1
protein while upregulating XPO1 message, indicative of
direct effects on the intended target. The biologic effects
of KPT-335 were demonstrated when cells were treated
with nanomolar concentrations of drug which have been
shown to be biologically achievable in dogs following
oral administration. These data lay the groundwork for
future clinical evaluation of KPT-335 in dogs with malig-
nant melanoma.
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